Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varnimcabtagene Autoleucel - Immuneel Therapeutics

Drug Profile

Varnimcabtagene Autoleucel - Immuneel Therapeutics

Alternative Names: ARI-0001; IMN-003A; var-cel

Latest Information Update: 22 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hospital Clinic de Barcelona; Institut d Investigacions Biomediques
  • Developer Hospital Clinic de Barcelona; Immuneel Therapeutics; Institut d Investigacions Biomediques
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Precursor cell lymphoblastic leukaemia-lymphoma
  • Clinical Phase Unknown Non-Hodgkin's lymphoma

Most Recent Events

  • 09 Dec 2023 Efficacy data from phase I trial in Precursor cell lymphoblastic leukaemia-lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 09 Dec 2023 Updated efficacy and adverse events data from the phase I/II IMAGINE trial in Precursor cell lymphoblastic leukaemia-lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 28 Jul 2023 Efficacy and adverse events data from a pooled analysis in Non-Hodgkin's lymphoma and Precursor-cell lymphoblastic leukaemia lymphoma presented at the 28th Congress of the European Haematology Association (EHA-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top